Annual EBITDA
-$3.82 M
+$4.31 M+52.96%
31 December 2023
Summary:
Sunshine Biopharma annual earnings before interest, taxes, depreciation & amortization is currently -$3.82 million, with the most recent change of +$4.31 million (+52.96%) on 31 December 2023. During the last 3 years, it has fallen by -$3.26 million (-583.12%). SBFMW annual EBITDA is now -29043.26% below its all-time high of -$13.12 thousand, reached on 31 July 2007.SBFMW EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBITDA
-$933.11 K
+$140.30 K+13.07%
30 September 2024
Summary:
Sunshine Biopharma quarterly earnings before interest, taxes, depreciation & amortization is currently -$933.11 thousand, with the most recent change of +$140.30 thousand (+13.07%) on 30 September 2024. Over the past year, it has dropped by -$398.27 thousand (-74.47%). SBFMW quarterly EBITDA is now -161.70% below its all-time high of $1.51 million, reached on 30 September 2010.SBFMW Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBITDA
-$4.13 M
-$398.27 K-10.68%
30 September 2024
Summary:
Sunshine Biopharma TTM earnings before interest, taxes, depreciation & amortization is currently -$4.13 million, with the most recent change of -$398.27 thousand (-10.68%) on 30 September 2024. Over the past year, it has increased by +$3.65 million (+46.90%). SBFMW TTM EBITDA is now -482.44% below its all-time high of $1.08 million, reached on 31 March 2010.SBFMW TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
SBFMW EBITDA Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +53.0% | -74.5% | +46.9% |
| 3 y3 years | -583.1% | -89.2% | +48.3% |
| 5 y5 years | -92.3% | -191.7% | -368.1% |
SBFMW EBITDA High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -583.1% | +53.0% | -237.5% | +81.0% | -73.8% | +52.5% |
| 5 y | 5 years | -583.1% | +53.0% | -998.2% | +84.8% | -368.1% | +52.5% |
| alltime | all time | <-9999.0% | +53.0% | -161.7% | +84.8% | -482.4% | +52.5% |
Sunshine Biopharma EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$933.11 K(-13.1%) | -$4.13 M(+10.7%) |
| June 2024 | - | -$1.07 M(-7.8%) | -$3.73 M(+9.4%) |
| Mar 2024 | - | -$1.16 M(+21.6%) | -$3.41 M(-10.9%) |
| Dec 2023 | -$3.82 M(-53.0%) | -$957.25 K(+79.0%) | -$3.82 M(-50.8%) |
| Sept 2023 | - | -$534.83 K(-28.8%) | -$7.77 M(-10.6%) |
| June 2023 | - | -$751.69 K(-52.4%) | -$8.69 M(+2.4%) |
| Mar 2023 | - | -$1.58 M(-67.8%) | -$8.49 M(+4.4%) |
| Dec 2022 | -$8.13 M(+234.9%) | -$4.91 M(+236.9%) | -$8.13 M(+132.3%) |
| Sept 2022 | - | -$1.46 M(+166.0%) | -$3.50 M(+38.0%) |
| June 2022 | - | -$547.47 K(-55.1%) | -$2.54 M(+6.8%) |
| Mar 2022 | - | -$1.22 M(+341.4%) | -$2.38 M(-67.4%) |
| Dec 2021 | -$2.43 M(+333.6%) | -$276.45 K(-43.9%) | -$7.29 M(-8.7%) |
| Sept 2021 | - | -$493.08 K(+27.9%) | -$7.99 M(-2.2%) |
| June 2021 | - | -$385.40 K(-93.7%) | -$8.17 M(-2.7%) |
| Mar 2021 | - | -$6.13 M(+529.1%) | -$8.39 M(+257.6%) |
| Dec 2020 | -$559.81 K(-63.4%) | -$974.80 K(+44.8%) | -$2.35 M(+34.2%) |
| Sept 2020 | - | -$673.00 K(+9.5%) | -$1.75 M(+25.3%) |
| June 2020 | - | -$614.78 K(+623.5%) | -$1.40 M(+57.4%) |
| Mar 2020 | - | -$84.97 K(-77.4%) | -$886.48 K(-4.5%) |
| Dec 2019 | -$1.53 M(-23.0%) | -$376.06 K(+17.6%) | -$928.15 K(+5.3%) |
| Sept 2019 | - | -$319.88 K(+203.0%) | -$881.75 K(-37.3%) |
| June 2019 | - | -$105.57 K(-16.6%) | -$1.41 M(-26.6%) |
| Mar 2019 | - | -$126.64 K(-61.6%) | -$1.92 M(-3.6%) |
| Dec 2018 | -$1.99 M(+114.4%) | -$329.66 K(-61.0%) | -$1.99 M(+4.9%) |
| Sept 2018 | - | -$844.66 K(+37.1%) | -$1.90 M(+63.2%) |
| June 2018 | - | -$616.28 K(+210.8%) | -$1.16 M(+14.2%) |
| Mar 2018 | - | -$198.30 K(-16.4%) | -$1.02 M(+9.7%) |
| Dec 2017 | -$927.49 K(-0.5%) | -$237.34 K(+115.8%) | -$927.48 K(-8.2%) |
| Sept 2017 | - | -$109.97 K(-76.7%) | -$1.01 M(+0.9%) |
| June 2017 | - | -$471.71 K(+334.9%) | -$1.00 M(+1.6%) |
| Mar 2017 | - | -$108.47 K(-66.2%) | -$986.40 K(+5.8%) |
| Dec 2016 | -$932.38 K | -$320.54 K(+217.2%) | -$932.38 K(+18.6%) |
| Sept 2016 | - | -$101.05 K(-77.9%) | -$786.08 K(-1.5%) |
| June 2016 | - | -$456.35 K(+738.3%) | -$798.08 K(+12.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2016 | - | -$54.44 K(-68.8%) | -$709.89 K(-9.0%) |
| Dec 2015 | -$776.03 K(-55.8%) | -$174.24 K(+54.1%) | -$780.28 K(-14.5%) |
| Sept 2015 | - | -$113.05 K(-69.3%) | -$912.34 K(-15.3%) |
| June 2015 | - | -$368.16 K(+194.9%) | -$1.08 M(-27.0%) |
| Mar 2015 | - | -$124.83 K(-59.2%) | -$1.47 M(-16.0%) |
| Dec 2014 | -$1.76 M(-9.3%) | -$306.30 K(+10.4%) | -$1.76 M(-17.8%) |
| Sept 2014 | - | -$277.43 K(-63.8%) | -$2.13 M(+4.9%) |
| June 2014 | - | -$765.51 K(+88.6%) | -$2.03 M(+43.1%) |
| Mar 2014 | - | -$405.87 K(-40.8%) | -$1.42 M(-26.7%) |
| Dec 2013 | -$1.94 M(+174.0%) | -$685.41 K(+285.7%) | -$1.94 M(+34.5%) |
| Sept 2013 | - | -$177.68 K(+16.4%) | -$1.44 M(-12.1%) |
| June 2013 | - | -$152.59 K(-83.5%) | -$1.64 M(+3.1%) |
| Mar 2013 | - | -$922.89 K(+390.2%) | -$1.59 M(+125.0%) |
| Dec 2012 | -$706.68 K(+27.1%) | -$188.26 K(-50.0%) | -$706.68 K(-20.6%) |
| Sept 2012 | - | -$376.41 K(+266.5%) | -$890.48 K(+41.2%) |
| June 2012 | - | -$102.69 K(+161.1%) | -$630.51 K(+15.8%) |
| Mar 2012 | - | -$39.33 K(-89.4%) | -$544.31 K(-1.8%) |
| Dec 2011 | -$556.20 K(+3.5%) | -$372.06 K(+219.5%) | -$554.20 K(-15.9%) |
| Sept 2011 | - | -$116.44 K(+606.1%) | -$659.09 K(-168.0%) |
| June 2011 | - | -$16.49 K(-66.5%) | $969.62 K(-261.1%) |
| Mar 2011 | - | -$49.22 K(-89.7%) | -$601.95 K(+12.0%) |
| Dec 2010 | -$537.38 K(+1960.6%) | -$476.95 K(-131.5%) | -$537.38 K(+789.2%) |
| Sept 2010 | - | $1.51 M(-195.2%) | -$60.44 K(-88.0%) |
| June 2010 | - | -$1.59 M(<-9900.0%) | -$503.59 K(-146.7%) |
| Mar 2010 | - | $15.35 K(-98.6%) | $1.08 M(+2.0%) |
| Oct 2009 | - | $1.07 M(<-9900.0%) | $1.06 M(-6860.2%) |
| July 2009 | - | -$5191.00(+110.2%) | -$15.65 K(+6.4%) |
| Apr 2009 | - | -$2470.00(-26.3%) | -$14.70 K(-36.1%) |
| Jan 2009 | - | -$3353.00(-27.7%) | -$23.02 K(+5.0%) |
| Oct 2008 | - | -$4638.00(+9.3%) | -$21.93 K(-15.9%) |
| July 2008 | -$26.08 K(+98.7%) | -$4243.00(-60.6%) | -$26.08 K(+19.4%) |
| Apr 2008 | - | -$10.78 K(+376.0%) | -$21.84 K(+97.5%) |
| Jan 2008 | - | -$2265.00(-74.2%) | -$11.05 K(+25.8%) |
| Oct 2007 | - | -$8788.00 | -$8788.00 |
| July 2007 | -$13.12 K | - | - |
FAQ
- What is Sunshine Biopharma annual earnings before interest, taxes, depreciation & amortization?
- What is the all time high annual EBITDA for Sunshine Biopharma?
- What is Sunshine Biopharma annual EBITDA year-on-year change?
- What is Sunshine Biopharma quarterly earnings before interest, taxes, depreciation & amortization?
- What is the all time high quarterly EBITDA for Sunshine Biopharma?
- What is Sunshine Biopharma quarterly EBITDA year-on-year change?
- What is Sunshine Biopharma TTM earnings before interest, taxes, depreciation & amortization?
- What is the all time high TTM EBITDA for Sunshine Biopharma?
- What is Sunshine Biopharma TTM EBITDA year-on-year change?
What is Sunshine Biopharma annual earnings before interest, taxes, depreciation & amortization?
The current annual EBITDA of SBFMW is -$3.82 M
What is the all time high annual EBITDA for Sunshine Biopharma?
Sunshine Biopharma all-time high annual earnings before interest, taxes, depreciation & amortization is -$13.12 K
What is Sunshine Biopharma annual EBITDA year-on-year change?
Over the past year, SBFMW annual earnings before interest, taxes, depreciation & amortization has changed by +$4.31 M (+52.96%)
What is Sunshine Biopharma quarterly earnings before interest, taxes, depreciation & amortization?
The current quarterly EBITDA of SBFMW is -$933.11 K
What is the all time high quarterly EBITDA for Sunshine Biopharma?
Sunshine Biopharma all-time high quarterly earnings before interest, taxes, depreciation & amortization is $1.51 M
What is Sunshine Biopharma quarterly EBITDA year-on-year change?
Over the past year, SBFMW quarterly earnings before interest, taxes, depreciation & amortization has changed by -$398.27 K (-74.47%)
What is Sunshine Biopharma TTM earnings before interest, taxes, depreciation & amortization?
The current TTM EBITDA of SBFMW is -$4.13 M
What is the all time high TTM EBITDA for Sunshine Biopharma?
Sunshine Biopharma all-time high TTM earnings before interest, taxes, depreciation & amortization is $1.08 M
What is Sunshine Biopharma TTM EBITDA year-on-year change?
Over the past year, SBFMW TTM earnings before interest, taxes, depreciation & amortization has changed by +$3.65 M (+46.90%)